Advanced host cell protein (HCP) analysis with TIMS QTOF MS powers biopharmaceutical development

Significance of the topic

Biotherapeutic development has surged in recent years as large molecule drugs and biosimilars address critical medical needs. This growth demands analytical methods capable of rigorously detecting trace impurities, especially host cell proteins (HCPs), to ensure product safety, efficacy and regulatory compliance.

Objectives and Overview

This whitepaper explores advanced mass spectrometry strategies for comprehensive HCP analysis. It compares conventional immunoassays with novel TIMS QTOF MS workflows employing PASEF technology for both deep discovery and rapid screening of residual HCPs in biopharmaceuticals.

Methodology and Instrumentation

The study highlights two primary workflows:

• HCP discovery via nanoLC coupled to trapped ion mobility spectrometry (TIMS) QTOF MS with parallel accumulation–serial fragmentation (PASEF), enabling long gradients (>2 h) for maximal protein coverage.
• Fast HCP screening using Evosep One low-flow chromatography with TIMS QTOF MS and a 21 min gradient to identify >50 HCPs at 1% false discovery rate.

The key instrument is the timsTOF Pro platform, which integrates high-resolution liquid chromatography, gas-phase ion mobility separation and high-speed MS/MS acquisition (>100 Hz).

Main Results and Discussion

Deep discovery runs identified up to 280 HCPs in a 1.5 µg NISTmAb digest, using both native and denaturing tryptic protocols. Fast screening detected 50+ HCPs reproducibly in under 30 min. The additional TIMS dimension improved dynamic range and reduced interference, enabling direct quantitation of low-ppm HCPs. Comparative evaluation of data-dependent (DDA) and data-independent (diaPASEF) acquisition modes demonstrated enhanced depth and consistency, supporting both qualitative and quantitative HCP profiling.

Benefits and Practical Applications

• Non-targeted detection and quantification of individual HCPs as critical quality attributes.
• High sensitivity for sub-100 ppm HCPs, reducing immunogenic risk.
• Single-run workflows that combine deep discovery and routine screening.
• Robust process fingerprinting for batch-to-batch comparability.

Future Trends and Applications

Emerging DIA strategies like diaPASEF will further increase proteome coverage and quantitation accuracy. Integration with ultrafast LC platforms and automated data analysis pipelines promises sub-10 min end-to-end HCP monitoring. Ion mobility-based CCS values will become standard for robust peptide identification across changing chromatographic conditions.

Conclusion

TIMS QTOF MS with PASEF delivers a versatile, high-throughput solution for HCP analysis, offering both comprehensive discovery and rapid screening in a single platform. This approach enhances impurity control, accelerates process development and supports adherence to stringent regulatory requirements.

Reference

• [1] Therapeutic Product R D Market Trends, Pharm Tech, 2017.
• [2] Ecker DM, Jones SD and Levine HL, The therapeutic monoclonal antibody market, MAbs, 7, 2015.
• [3] Fischer SK et al., Specific Immune Response to Phospholipase B-Like 2 Protein, AAPS J, 19(1):254-263, 2017.
• [4] Richter W et al., Refolding, purification, and characterization of human recombinant PDE4A constructs, Protein Expr Purif, 19(3):375-383, 2000.
• [5] Siew A, Impurity Testing of Biologic Drug Products, BioPharm Int, 31(2):14-19, 2018.
• [6] Huang L et al., A novel sample preparation for shotgun proteomics characterization of HCPs, Anal Chem, 86:5436-5444, 2017.
• [7] Reisinger V et al., A mass spectrometry-based approach to host cell protein identification, Anal Biochem, 463:1-6, 2014.
• [8] Bache N et al., A novel LC system embeds analytes in pre-formed gradients for rapid, ultra-robust proteomics, Mol Cell Proteomics, 2018.
• [9] Meier F et al., Parallel accumulation serial fragmentation combined with data independent acquisition diaPASEF, bioRxiv, 2019.